Lumacaftor 100 mg / ivacaftor 125 mg Oral Tablet
RxNorm 1812468
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1812468 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: lumacaftor 100 mg / ivacaftor 125 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Ivacaftor 125 mg / lumacaftor 100 mg Oral Tablet
(Atom ID: 8261898)
PSNPrescribable
Prescribable Name (PSN):
Lumacaftor 100 mg / ivacaftor 125 mg Oral Tablet
(Atom ID: 8261903)
Patient Education
Lumacaftor and Ivacaftor
Lumacaftor and ivacaftor is used to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 2 years of age and older. Lumacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) correctors. Ivacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) potentiators. Both of these medications work by improving the function of a protein in the body to decrease the build-up of thick mucus in the lungs and improving other symptoms of cystic fibrosis.
[Learn More]
* Please review the disclaimer below.